secwatch.observer — SEC 8-K summary
======================================

Issuer:     JANEL CORP (JANL)
CIK:        0001133062
Form:       8-K
Filed at:   2026-10-22T21:00:27+00:00
Accession:  0001140361-26-040525
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 2.03, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Janel acquires EnCor Biotechnology for $17M; $11.96M cash plus $5.04M subordinated note
--------------------------------------------------------------------------------

- On Oct. 20, 2026, Janel's Antibodies Incorporated bought 100% of Gainesville, Florida-based EnCor Biotechnology, an antibody/reagent maker for neurological disease research.
- Base purchase price $17.0M: $11.96M cash at closing plus $5.04M subordinated promissory note; sellers include Gerry Shaw, University of Florida Research Foundation and employee shareholders.
- Deferred payments to Shaw of $1.68M each on the first, second and third anniversaries; first payment subject to working-capital adjustment versus $250,000 target.
- On Oct. 16, 2026, lenders increased the acquisition facility by $15M; $11M was funded at closing, and EnCor joined as a borrower.
- Janel is seeking SEC relief from Rule 3-05 audited EnCor financials, arguing they are not material; no historical or pro forma statements were filed yet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133062/000114036126040525/0001140361-26-040525-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133062/000114036126040525/ef20084224_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-040525

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer